Tags : Pulmatrix

PharmaShots Weekly Snapshot (Dec 30, 2019-Jan 03, 2020)

Vartika Singh January 6, 2020

1. RedHill Terminates its 2014 Deal with Salix Pharmaceuticals for RHB-106 Published: Jan 03, 2019 | Tags: 2014, Deal, RedHill, RHB-106, Salix Pharmaceuticals, Terminates 2. Innate’s Lumoxiti (moxetumomab pasudotox-tdfk) Receives […]readmore

Biotech

Johnson & Johnson Signs a License Agreement with Pulmatrix to

Vartika Singh January 3, 2020

Shots: Pulamtrix to receive $7.2M up front, milestones up to $2M on completion of P-Ib study of RV1162/PUR1800 for patients with COPD, with on-track for year-end 2020 from J&J’s Lung […]readmore

Tags : Pulmatrix

PharmaShots Weekly Snapshot (Dec 30, 2019-Jan 03, 2020)

Johnson & Johnson Signs a License Agreement with Pulmatrix to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Pulmatrix

PharmaShots Weekly Snapshot (Dec 30, 2019-Jan 03, 2020)

Johnson & Johnson Signs a License Agreement with Pulmatrix to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company